What is the pathophysiology of muscle loss in liver cirrhosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Muscle loss in liver cirrhosis, known as sarcopenia, occurs due to multiple factors related to liver dysfunction, including altered protein metabolism, impaired hepatic ammonia clearance, and metabolic disturbances, as highlighted in the 2021 practice guidance by the American Association for the Study of Liver Diseases 1. The primary mechanisms of muscle loss in liver cirrhosis include:

  • Reduced protein synthesis: The liver's impaired ability to produce proteins leads to decreased muscle protein production.
  • Increased protein breakdown: Cirrhosis causes elevated levels of inflammatory cytokines, which promote muscle protein breakdown.
  • Metabolic disturbances: Altered glucose metabolism and insulin resistance contribute to muscle wasting.
  • Malnutrition: Poor appetite, malabsorption, and dietary restrictions often lead to inadequate nutrient intake.
  • Reduced physical activity: Fatigue and complications of cirrhosis often result in decreased physical activity, further promoting muscle loss.
  • Hormonal imbalances: Reduced testosterone levels and growth hormone resistance contribute to muscle atrophy. To address muscle loss in cirrhosis patients:
  • Ensure adequate protein intake (1.2-1.5 g/kg/day) through diet or supplements, as recommended by the EASL clinical practice guidelines on nutrition in chronic liver disease 1.
  • Encourage regular physical activity, including resistance exercises, as tolerated, to improve muscle mass and function, as suggested by the EASL clinical practice guidelines on nutrition in chronic liver disease 1 and the KASL clinical practice guidelines for liver cirrhosis 1.
  • Treat underlying nutritional deficiencies (e.g., vitamin D, zinc) to support muscle health.
  • Consider branched-chain amino acid supplementation (0.25 g/kg/day) to support muscle protein synthesis.
  • Manage complications of cirrhosis that may contribute to muscle loss, such as hepatic encephalopathy and ascites. The most recent and highest quality study, the 2024 EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) 1, recommends a high-protein diet and a late-evening snack for adults with sarcopenia, sarcopenic obesity, or decompensated cirrhosis, and emphasizes the importance of maintaining muscle mass and reducing the risk of sarcopenia.

From the Research

Pathophysiology of Muscle Loss in Liver Cirrhosis

The pathophysiology of muscle loss in liver cirrhosis is complex and multifactorial. Key factors contributing to muscle loss include:

  • Poor nutritional intake 2
  • Protein catabolism 3
  • Physical inactivity 2
  • Hyperammonemia, which is the best-studied mediator of the liver-muscle axis 3
  • Impaired skeletal muscle protein synthesis and increased proteolysis via autophagy 3
  • Increased expression of myostatin 3
  • Impaired mitochondrial function and tricarboxylic acid cycle intermediates 3

Consequences of Muscle Loss

Muscle loss in liver cirrhosis has significant consequences, including:

  • Increased mortality 4, 5, 6
  • Increased risk of sepsis-related mortality 6
  • Increased risk of development of other complications of cirrhosis, such as hepatic encephalopathy 4
  • Worsened post-liver transplant outcomes 3
  • Decreased quality of life 3, 2

Assessment and Management

Assessment of muscle loss in liver cirrhosis can be done using cross-sectional imaging studies, such as computed tomography (CT) scan or magnetic resonance imaging (MRI) 5. Management of muscle loss includes:

  • High protein diets 2
  • Combination aerobic/resistance exercise 2
  • Potential future therapeutic options, such as myostatin antagonists, specific amino acid supplementation, mitochondrial protection, and combination endurance-resistance exercise 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Sarcopenia in cirrhosis: A practical overview.

Clinical medicine (London, England), 2020

Research

Cause and management of muscle wasting in chronic liver disease.

Current opinion in gastroenterology, 2016

Research

Role of Nutrition and Muscle in Cirrhosis.

Current treatment options in gastroenterology, 2016

Research

Muscle wasting: a nutritional criterion to prioritize patients for liver transplantation.

Current opinion in clinical nutrition and metabolic care, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.